Avastin risks outweighed benefits in 1 study: FDA
Tuesday, July 20, 2010 - 13:42
in Health & Medicine
A follow-up study of the Roche drug Avastin failed to show meaningful benefits for breast cancer patients, a U.S. Food and Drug Administration panel of experts reviewing the drug has unanimously concluded.